Results 61 to 70 of about 3,018,484 (379)

Judicial and legislative practice and related suggestions on off-label drug use in China

BMC Health Services Research, 2023
Background Off-label drug use exists widely in medical practice and is also an area which easily triggers controversy between patients and medical institutions. Previous studies have identified the reasons why off-label drug use long exists.
Wenjie Si, Panpan Ma
doaj   +1 more source

An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics

Medicina, 2022
In recent years, off-label and unlicensed drug use has extensively developed in the paediatric population. For a long time, clinical trials in the paediatric population were considered complicated to perform because of ethical problems, causing frequent ...
Roberto Bernardini, Gaia Toschi Vespasiani, Arianna Giannetti   +2 more
doaj   +1 more source

Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System

Frontiers in Pharmacology, 2020
Background Among factors influencing the higher risk of developing unknown or rare adverse drug reactions (ADRs) among children and adolescents, there is the frequent off-label use of drugs that seems to be very common in pediatric oncological patients ...
A. Mascolo, C. Scavone, Michele Bertini, Simona Brusco, F. Punzo, E. Pota, M. di Martino, Daniela Di Pinto, F. Rossi   +8 more
semanticscholar   +1 more source

Nutritional and Behavioral Intervention for Long‐Term Childhood Acute Leukemia Survivors With Metabolic Syndrome

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Metabolic syndrome (MetS) is a common complication in survivors of childhood acute lymphoblastic and myeloid leukemia (AL), and a major risk factor for premature cardiovascular disease, type‐2‐diabetes, and metabolic dysfunction‐associated steatotic liver disease (MASLD).
Visentin Sandrine, Béliard Sophie, Renard Cécile, Caussy Cyrielle, Hamidou Zeinab, Romano David, Gacem Mélanie, Petit Arnaud, Saultier Paul, Borentain Patrick, Michel Gérard   +10 more
wiley   +1 more source

Current practice and awareness of pediatric off-label drug use in Shanghai, China -a questionnaire-based study

BMC Pediatrics, 2019
Background Off-label drug use is widespread in pediatric drug treatment, and the implementation of guidelines on this topic remains challenging. The objective of this study was to evaluate current practice and awareness of healthcare professionals ...
Mei Mei, Hong Xu, Libo Wang, Guoying Huang, Yonghao Gui, Xiaobo Zhang   +5 more
doaj   +1 more source

Off-Label Use of Bumetanide for Brain Disorders: An Overview

Frontiers in Neuroscience, 2019
Bumetanide (BTN or BUM) is a FDA-approved potent loop diuretic (LD) that acts by antagonizing sodium-potassium-chloride (Na-K-Cl) cotransporters, NKCC1 (SLc12a2) and NKCC2.
Shivani C. Kharod, S. K. Kang, S. Kadam
semanticscholar   +1 more source

RT‐PCR–Based Detection of Bone Marrow Involvement in Ewing Sarcoma: Diagnostic Validity and Prognostic Relevance

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background In Ewing sarcoma (EwS), metastases, including those to bone marrow (BM), are the main factors influencing prognosis. Although reverse transcription polymerase chain reaction (RT‐PCR) offers greater sensitivity, the current EWING protocol defines BM metastases solely using light microscopic detection.
Thanh Pham, Andreas Ranft, Victor Rechl, Susanne Jabar, Wolfgang Hartmann, Kim Falkenberg, Heribert Jürgens, Norbert Graf, Torsten Keßler, Markus Metzler, Thomas Klingebiel, Thorsten Simon, Martin Benesch, Uta Dirksen   +13 more
wiley   +1 more source

Itraconazole in the Treatment of Nonfungal Cutaneous Diseases: A Review

Dermatology and Therapy, 2019
Introduction The anti-inflammatory and pro-kinetic properties of antibiotics have been widely reported. However, the non-antifungal properties of antifungal agents are less well known and less explored in clinical practice. The purpose of this review was
Ya-Chu Tsai, Tsen-Fang Tsai
doaj   +1 more source

Oncogenic NRAS Mutation in Incipient Sarcomatous Transformation of Cystic Nephroma From a Patient With DICER1‐Related Tumor Predisposition Syndrome

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Anaplastic sarcoma of the kidney (ASK) is a DICER1‐associated malignant tumor presumed to arise in a benign precursor, pediatric cystic nephroma (PCN). However, the initial oncogenic alteration(s) associated with malignant transformation are unknown.
Nahir Cortes‐Santiago, Sarah B. Whittle, Sarah Scollon, Sharon E. Plon, Sanjeev Vasudevan, Bryony J. Lucas, Angshumoy Roy   +6 more
wiley   +1 more source

Off-label use of rituximab for systemic lupus erythematosus in Europe [PDF]

, 2018
K
Boumpas, Dimitrios, Bultink, Irene, Callejas Rubio, Jose Luis, Caminal-Montero, Luis, Castro, Antoni, Colodro Ruiz, Agustín, Doria, Andrea, Dörner, Thomas, Gonzalez-Echavarri, Cristina, Gremese, Elisa, Houssiau, Frederic A, Huizinga, Tom, Inanç, Murat, Isenberg, David, Iuliano, Annamaria, Jacobsen, Søren, Jimenéz-Alonso, Juan, Kovács, Lászlo, Mariette, Xavier, Mosca, Marta, Nived, Ola, Oristrell, Joaquim, Ramos-Casals, Manuel, Rascón, Javier, Ruiz-Irastorza, Guillermo, Rydén-Aulin, Monica, Salvador Cervelló, Gonzalo, Sebastiani, Gian Domenico, Squatrito, Danilo, Szücs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus), Szücs, Gabriella, Sáez-Comet, Luis, van Vollenhoven, Ronald, Voskuyl, Alexandre   +33 more
core   +1 more source